In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

End Game: Adrenomed Targets Global Reach For Sepsis Candidate

Executive Summary

German biotech Adrenomed has proof-of-concept data showing its sepsis drug can cut mortality by 67%. Now, it needs money to move the candidate into Phase IIb/III trials.

You may also be interested in...



Revamped Modus Switches To Sepsis, Septic Shock For Sevuparin

After disappointment in sickle cell anemia, Modus Therapeutics will now develop its lead asset sevuparin as a treatment for sepsis and septic shock and plans a public listing in Sweden to fund the new strategy, its CEO tells Scrip.

Yabao Links With Lawson For Innovative Sepsis Drug

With the aim of providing new cures for a global unmet medical need in sepsis, China’s Yabao Pharmaceutical and its strategic partner Lawson have completed discovery validation work for annexin A5-based products under a newly announced license agreement. An IND filing is expected in 2016.

Next Wave: The Early Pipeline For Sepsis And Related Conditions

New approaches to sepsis therapy in early development aim to modulate immune and inflammatory response without the negative effects of generalized immunosuppression.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel